2022 Annual Meeting | C75 - Neuro-oncology: Navigating Current Trends

Date Monday 04/04/22

Time 01:00 PM - 03:00 PM PDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Maciej M. Mrugala, MD, PhD, MPH, FAAN

Topic(s) Neuro-oncology

Learning Objectives The learners will be able to acquire knowledge on the new WHO CNS tumors classification. New targeted therapies available to a neuro-oncologist will be discussed in detail. The faculty will cover both primary and metastatic brain tumors. Recent FDA-approved agents for the treatment of NF1 associated plexiform neurofibromas, as well as Von-Hipple Lindau disease-associated tumors, will be discussed.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge, Practice-based Learning and Improvement

Program Level Intermediate

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider, Neurohospitalist

Teaching Styles Case-based, Didactic

Program Materials Program Evaluations

Event Timeline
01:00 PM - 01:05 PM PDT	Introduction	Introduction Maciej M. Mrugala, MD, PhD, MPH, FAAN
01:00 PM - 01:00 PM PDT	Speaker	walk in slides Maciej M. Mrugala, MD, PhD, MPH, FAAN
01:05 PM - 01:40 PM PDT	Speaker	Contemporary Approach to Metastatic Disease in the CNS Wendy Sherman, MD
01:40 PM - 02:20 PM PDT	Speaker	Deeper Dive into WHO CNS5 Classification with Practical Implications for a Neuro-oncologist Craig Horbinski, MD
02:20 PM - 02:40 PM PDT	Speaker	Targeted Therapy in Neuro-oncology Clinic - Expanding Menu of Options Maciej M. Mrugala, MD, PhD, MPH, FAAN
02:40 PM - 03:00 PM PDT	Discussion	Discussion & Questions and Answers Maciej M. Mrugala, MD, PhD, MPH, FAAN, Craig Horbinski, MD, Wendy Sherman, MD

Faculty Disclosures
Maciej M. Mrugala, MD, PhD, MPH, FAAN	Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Veevo Biomedicines Inc. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arbor Pharmaceuticals. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra-Zeneca. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Mrugala has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Kyiatec . The institution of Dr. Mrugala has received research support from Arbor Pharmaceuticals. Dr. Mrugala has a non-compensated relationship as a Program Director with Society for Neuro-Oncology that is relevant to AAN interests or activities.
Craig Horbinski, MD	Craig Horbinski, MD has nothing to disclose.
Wendy Sherman, MD	Dr. Sherman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Focused ultrasound foundation . Dr. Sherman has received personal compensation in the range of $500-$4,999 for serving as a Advisory Board Member with Kiyatec.